Inventor · disambiguated record
Brian E. Cathers
Also filed as: CATHERS BRIAN · CATHERS BRIAN E · CATHERS BRIAN EDWIN
18 granted patents·8 pending applications·176 citations·filing 2001–2024
94Inventor score
Top patents by PatentIndex Score
26 records- 0197US9499514B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2015·Granted Nov 22, 2016·28 cites·29 claims
- 0296US11185543B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2020·Granted Nov 30, 2021·5 cites·20 claims
- 0395US10357489B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2018·Granted Jul 23, 2019·20 cites·26 claims
- 0494US9808451B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2016·Granted Nov 7, 2017·12 cites·19 claims
- 0593US7759342B2Methods of treatment and prevention using haloaryl substituted aminopurinesSIGNAL PHARM LLC·Filed 2007·Granted Jul 20, 2010·35 cites·7 claims
- 0692US9968596B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2017·Granted May 15, 2018·8 cites·26 claims
- 0790US11241423B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2019·Granted Feb 8, 2022·2 cites·6 claims
- 0889US9556126B2Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2014·Granted Jan 31, 2017·10 cites·32 claims
- 0989US8440661B2Methods of modulating inflammatory cell recruitment and gene expression using haloaryl substituted aminopurinesBENNETT BRYDON L·Filed 2010·Granted May 14, 2013·21 cites·26 claims
- 1088US10668057B2Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligasesCELGENE CORP·Filed 2018·Granted Jun 2, 2020·3 cites·7 claims
- 1188US10092555B2Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligasesCELGENE CORP·Filed 2015·Granted Oct 9, 2018·8 cites·7 claims
- 1286US9156798B2Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2015·Granted Oct 13, 2015·5 cites·30 claims
- 1383US11419861B2Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligasesCELGENE CORP·Filed 2020·Granted Aug 23, 2022·1 cites·7 claims
- 1483US8680076B2Methods of treatment, improvement and prevention using haloaryl substituted aminopurinesBENNETT BRYDON L·Filed 2011·Granted Mar 25, 2014·15 cites·18 claims
- 1582US2024207255A1Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2024·Application pending·0 cites
- 1679US9783505B2Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2016·Granted Oct 10, 2017·2 cites·29 claims
- 1779US2022387413A1Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2021·Application pending·0 cites
- 1878US10830762B2Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligasesCELGENE CORP·Filed 2016·Granted Nov 10, 2020·1 cites·8 claims
- 1977US12029738B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2021·Granted Jul 9, 2024·0 cites·23 claims
- 2070US11733233B2Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligasesCELGENE CORP·Filed 2020·Granted Aug 22, 2023·0 cites·17 claims
- 2164US2018221361A1Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2018·Application pending·0 cites
- 2254US2023159538A1Pyrrolidine-pyrazoles as pyruvate kinase activatorsGLOBAL BLOOD THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2352US2023278984A1Urea derivatives as pyruvate kinase activatorsGLOBAL BLOOD THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2450US2003114385A1Viral enzyme activated prototoxophores and use of same to treat viral infectionsFiled 2002·Application pending·0 cites
- 2546US2003130179A1Methods for identifying therapeutic targets for treating infectious diseaseFiled 2001·Application pending·0 cites
- 2635US2018267043A1Use of biomarkers for predicting clinical sensitivity to cancer treatmentCELGENE CORP·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Brian E. Cathers files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →